$1.61
+0.06 (+3.87%)
Open$1.54
Previous Close$1.55
Day High$1.62
Day Low$1.50
52W High$2.98
52W Low$1.30
Volume—
Avg Volume737.7K
Market Cap104.33M
P/E Ratio—
EPS$-1.93
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+1,118.0% upside
Current
$1.61
$1.61
Target
$19.61
$19.61
$14.26
$19.61 avg
$29.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 92.4K | 498.9K | 29.02M |
| Net Income | -119,628,202 | -581,032,821 | -227,719 |
| Profit Margin | -130,006.0% | -123,505.7% | -0.8% |
| EBITDA | -123,999,448 | -635,723,019 | -290,155 |
| Free Cash Flow | — | — | -255,634 |
| Rev Growth | -81.5% | -81.5% | +16.9% |
| Debt/Equity | — | — | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |